WEST VIRGINIA LEGISLATURE

2020 REGULAR SESSION

Introduced

House Bill 4195

FISCAL NOTE

By Delegate Pyles

[Introduced January 14, 2020; Referred to the Committee on Health and Human Resources then the Judiciary]

A BILL to amend the Code of West Virginia, 1931, as amended, by adding thereto a new article, designated §19-38-1, §19-38-2 and §19-38-3; to amend said code by adding thereto a new article, designated §51-12-1 and §51-12-2; to amend and reenact §60A-2-204 of said code; and to amend said code by adding thereto a new section, designated §61-11-27, all relating to the normalization of cannabis laws; providing legislative findings; permitting adult uses of cannabis; providing for cannabis testing; prohibiting state civil asset forfeiture; providing notice of transitional services to incarcerated offenders; requiring the expungement of cannabis offender records.

Be it enacted by the Legislature of West Virginia:

CHAPTER 19. AGRICULTURE.

ARTICLE 38. NORMALIZATION OF CANNABIS ACT.

§19-38-1. Legislative findings; and authorizing testing services.

(a) The Legislature of West Virginia recognizes the economic development opportunities of industrial hemp research and development and the economic potential of industrial hemp production in this state, and further recognizes the potential medicinal benefits of cannabis as provided for in chapter 16A of this code. The Legislature finds the normalization of cannabis laws is necessary to protect the civil rights and liberties of the citizens of this state from undue government interference. By the states recognizing the medical benefits of cannabis, the former inclusion of cannabis in the schedule of drugs that have no medicinal value, the Federal Law prohibiting a lawful use of cannabis is hereby nullified by the enactment of medical cannabis laws in 31 states, the District of Columbia and Puerto Rico, a majority of the states in these United States of America. Upon the passage of this article during the 2020 Regular Session of the Legislature, this act shall be known as the "Normalization of Cannabis Act" for the purpose of authorizing adult personal use of cannabis in this state.

(b) The Commissioner of Agriculture is hereby authorized to offer laboratory testing

services in state facilities, permit institutions of higher education to test, and contract for testing industrial hemp, pursuant to §19-12E-1 et seq. of this code, for testing cannabis pursuant to the provisions of this article, and for testing medical cannabis pursuant to the provisions of §16A-1-1 et seq. of this code. The commissioner shall propose legislative rules pursuant to §29A-3-1 et seq. of this code and provide cannabis testing rules for consumable industrial hemp products, for cannabis that is given away by a responsible adult to another responsible adult pursuant to the provision of this article, and for cannabis given to a medical cannabis patient without remuneration, that shall include testing for:

22 (1) THC potency;

- 23 (2) Cannabinoid content;
 - (3) Presence of pesticides, mold, heavy metals and other criteria as commonly reviewed and screened for in other agricultural consumer products;
 - (4) A fee schedule for testing individual samples of cannabis that may be charged by the department or a vendor not to exceed \$45 per sample: *Provided*, That an institution of higher education may not charge a testing fee: *Providing*, *however*, That an individual who grows or possesses cannabis pursuant to this article may not be charged a fee where the cannabis is for personal use only; and
 - (5) A fee schedule for commercial operation testing of industrial, agricultural, medical and other forms of lawfully regulated cannabis.

§19-38-2. Normalization of cannabis; allowing adult use.

- (a) Adults who have reached 21 years of age in this state may use, grow, possess, transport and give away cannabis and homemade cannabis products without remuneration pursuant to the provisions of this section: *Provided*, That the cannabis is for personal use only.
- 4 (b) "Personal use" means growing, processing, consuming or giving away cannabis

 without remuneration.
 - (c) An adult who is at least 21 years of age may grow up to 12 mature flowering cannabis

plants and have up to 12 cannabis sprouts or seedlings for personal use. Personal growing of
 cannabis by adults in a residence where children under the age of 18 reside shall keep the plants
 under lock and key and restrict access to the minors in the residence.
 (d) An adult who is at least 21 years of age may possess no greater than 226 grams of

(d) An adult who is at least 21 years of age may possess no greater than 226 grams of dry cannabis flower and leaf: *Provided*, That no adult may transport more than 60 grams of cannabis.

(e) An adult who is at least 21 years of age may giveaway without remuneration no greater than 30 grams of cannabis to another adult who is at least 21 years of age, or to a qualifying medical cannabis patient pursuant to the provisions of Chapter 16A of this code.

(f) Nothing in this prevents the state from adopting and regulating the commercial production of cannabis or cannabis products in any form.

§19-38-3. Civil asset forfeiture prohibited; triple damages.

(a) No adult 21 years of age or older who, uses, grows, possess, processes or gives away cannabis pursuant to the provisions of this article, may be forced to suffer or surrender personal property of any kind pursuant to any provision of §60A-7-701 *et seq.* of this code, who is in substantial compliance with the provisions of this article.

(b) An adult 21 years of age or older, who is forced to suffer or surrender personal property of any kind pursuant to any provision of §60A-7-701 *et seq.* of this code, is entitled to triple damages in any court in this state, including in the county where the offence occurred or in the Circuit of Kanawha County.

CHAPTER 51. COURTS AND THEIR OFFICERS.

ARTICLE 12. OFFENDER RELEASE TRANSITIONAL SERVICES.

§51-12-1. Legislative findings.

11

12

13

14

15

16

17

1

2

3

4

5

6

7

8

1

2

(a) The Legislature finds that, upon the enactment of the Normalization of Cannabis Act pursuant to the provisions of §19-38-1 et seq. of this code, during the 2020 Regular Session, and

for other persons who have served a sentence and are pending release from any correctional

facility in this state, those individuals shall be provided transitional services in order to facilitate a

successful reentry into society.

(b) Upon the effective date of this section as adopted during the 2020 Regular Session of the Legislature, the clerk of the circuit court and the prosecuting attorney of each county shall review all arrest and conviction record of every cannabis offender of every person convicted of a cannabis offense beginning in calendar year 1937 to the present, and not less than two months prior to the release of each person transitioning from an incarcerated status, each transitioning individual shall be notified by the circuit court in writing about the transitional services available as required by this article, including services offered prior to and upon release from any correctional facility in this state.

§51-12-2. Required training.

6

7

8

9

10

11

12

13

1

2

3

4

5

6

- (a) Upon the effective date of this article, the court shall provide, contract for or partner with institutions of higher education to provide transitional services to transitioning cannabis and all other person's subject to release from a correctional facility.
- (b) Not less than two months prior to the release of any individual from a correctional facility, the court shall notify the individual of the date of their pending release and shall describe in detail the transitional services available prior to and after release.
- (c) The court shall provide details about the availability of the following transitional services
 that shall include at a minimum:
- 9 (1) Remedial education and Scholastic Assessment Test preparation;
- 10 (2) Counseling for mental health or substance abuse;
- 11 (3) Transitional housing:
- 12 (4) Job training; and
- (5) Any other services the court determines appropriate to recommend that may help
 transitioning individuals successfully reenter society.

CHAPTER 60A. UNIFORM CONTROLLED SUBSTANCES ACT.

ARTICLE 2. STANDARDS AND SCHEDULES.

§60A-2-204. Schedule I.

1	(a) Schedule I shall consist of the drugs and other substances, by whatever official name,
2	common or usual name, chemical name, or brand name designated, listed in this section including
3	their isomers, esters, ethers, salts and salts of isomers, esters and ethers, whenever the existence
4	of such isomers, esters, ethers and salts is possible within the specific chemical designation.
5	(b) Opiates.
6	Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl) -4-piperidinyl]—
7	phenylacetamide);
8	Acetylmethadol;
9	Allylprodine;
10	Alphacetylmethadol (except levoalphacetylmethadol also known as levo-alpha-
11	acetylmethadol, levomethadyl acetate, or LAAM);
12	Alphameprodine;
13	Alphamethadol;
14	Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl) ethyl-4-piperidyl] propionanilide;
15	1-(1-methyl-2-phenylethyl)-4-((propanilido) piperidine);
16	Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl) ethyl- 4-piperidinyl]—
17	phenylpropanamide);
18	Benzethidine;
19	Betacetylmethadol;
20	Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl) -4- piperidinyl]-N-
21	phenylpropanamide);

22	Beta-hydroxy-3-methylfentanyl (other name: N-[1-(2- hydroxy-2-phenethyl)-3-methyl-4-
23	piperidinyl]-N-phenylpropanamide);
24	Betameprodine;
25	Betamethadol;
26	Betaprodine;
27	Clonitazene;
28	Dextromoramide;
29	Diampromide;
30	Diethylthiambutene;
31	Difenoxin;
32	Dimenoxadol;
33	Dimepheptanol;
34	Dimethylthiambutene;
35	Dioxaphetyl butyrate;
36	Dipipanone;
37	Ethylmethylthiambutene;
38	Etonitazene;
39	Etoxeridine;
40	Furethidine;
41	Hydroxypethidine;
42	Ketobemidone;
43	Levomoramide;
44	Levophenacylmorphan;
45	3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4- piperidyl]-N-phenylpropanamide);
46	3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl) ethyl-4- piperidinyl]—phenylpropanamide);
47	Morpheridine;

48	MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
49	Noracymethadol;
50	Norlevorphanol;
51	Normethadone;
52	Norpipanone;
53	Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2- phenethyl)-4-piperidinyl] propanamide);
54	PEPAP(1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
55	Phenadoxone;
56	Phenampromide;
57	Phenomorphan;
58	Phenoperidine;
59	Piritramide;
60	Proheptazine;
61	Properidine;
62	Propiram;
63	Racemoramide;
64	Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4- piperidinyl]-propanamide);
65	Tilidine;
66	Trimeperidine.
67	(c) Opium derivatives:
68	Acetorphine;
69	Acetyldihydrocodeine;
70	Benzylmorphine;
71	Codeine methylbromide;
72	Codeine-N-Oxide;
73	Cyprenorphine;

74	Desomorphine;
75	Dihydromorphine;
76	Drotebanol;
77	Etorphine (except HCl Salt);
78	Heroin;
79	Hydromorphinol;
80	Methyldesorphine;
81	Methyldihydromorphine;
82	Morphine methylbromide;
83	Morphine methylsulfonate;
84	Morphine-N-Oxide;
85	Myrophine;
86	Nicocodeine;
87	Nicomorphine;
88	Normorphine;
89	Pholcodine;
90	Thebacon.
91	(d) Hallucinogenic substances.
92	Alpha-ethyltryptamine; some trade or other names: etryptamine; Monase; alpha-ethy-1H-
93	indole-3-ethanamine; 3-(2- aminobutyl) indole; alpha-ET; and AET;
94	4-bromo-2, 5-dimethoxy-amphetamine; some trade or other names: 4-bromo-2,5-
95	dimethoxy-alpha-methylphenethylamine; 4-bromo- 2,5-DMA;
96	4-Bromo-2,5-dimethoxyphenethylamine; some trade or other names: 2-(4-bromo-2,5-
97	dimethoxyphenyl)-1-aminoethane; alpha- desmethyl DOB; 2C-B, Nexus;
98	N-(2-Methoxybenzyl)-4-bromo-2, 5-dimethoxyphenethylamine. The substance has the
99	acronym 25B-NBOMe.

100	2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25C-NBOMe)
101	2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25I-NBOMe)
102	2,5-dimethoxyamphetamine; some trade or other names: 2,5-dimethoxy-alpha-
103	methylphenethylamine; 2,5-DMA;
104	2,5-dimethoxy-4-ethylamphet-amine; some trade or other names: DOET;
105	2,5-dimethoxy-4-(n)-propylthiophenethylamine (other name: 2C-T-7);
106	4-methoxyamphetamine; some trade or other names: 4-methoxy-alpha-
107	methylphenethylamine; paramethoxyamphetamine; PMA;
108	5-methoxy-3, 4-methylenedioxy-amphetamine;
109	4-methyl-2,5-dimethoxy-amphetamine; some trade and other names: 4-methyl-2,5-
110	dimethoxy-alpha-methylphenethylamine; "DOM"; and "STP";
111	3,4-methylenedioxy amphetamine;
112	3,4-methylenedioxymethamphetamine (MDMA);
113	3,4-methylenedioxy-N-ethylamphetamine (also known as (ethyl-alpha-methyl-3,4
114	(methylenedioxy) phenethylamine, N-ethyl MDA, MDE, MDEA);
115	N-hydroxy-3,4-methylenedioxyamphetamine (also known as (hydroxy-alpha-methyl-3,4
116	(methylenedioxy) phenethylamine, and (hydroxy MDA);
117	3,4,5-trimethoxy amphetamine;
118	5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
119	Alpha-methyltryptamine (other name: AMT);
120	Bufotenine; some trade and other names: 3-(beta-Dimethylaminoethyl)-5-
121	hydroxyindole;3-(2-dimethylaminoethyl) -5-indolol; N, N-dimethylserotonin; 5-hydroxy-N,N-
122	dimethyltryptamine; mappine;
123	Diethyltryptamine; sometrade and other names: N, N-Diethyltryptamine; DET;
124	Dimethyltryptamine; some trade or other names: DMT;
125	5-Methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);

126	Ibogaine; some trade and other names: 7-Ethyl-6, 6 Beta, 7, 8, 9, 10, 12, 13-octahydro-2-
127	methoxy-6, 9-methano-5H- pyrido [1', 2': 1, 2] azepino [5,4-b] indole; Tabernanthe iboga;
128	Lysergic acid diethylamide;
129	Marihuana;
130	Mescaline;
131	Parahexyl-7374; some trade or other names: 3-Hexyl -1-hydroxy-7, 8, 9, 10-tetrahydro-6,
132	6, 9-trimethyl-6H-dibenzo [b,d] pyran; Synhexyl;
133	Peyote; meaning all parts of the plant presently classified botanically as Lophophora
134	williamsii Lemaire, whether growing or not, the seeds thereof, any extract from any part of such
135	plant, and every compound, manufacture, salts, immediate derivative, mixture or preparation of
136	such plant, its seeds or extracts;
137	N-ethyl-3-piperidyl benzilate;
138	N-methyl-3-piperidyl benzilate;
139	Psilocybin;
140	Psilocyn;
141	Tetrahydrocannabinols; synthetic equivalents of the substances contained in the plant, or
142	in the resinous extractives of Cannabis, sp. and/or synthetic substances, immediate derivatives
143	and their isomers with similar chemical structure and pharmacological activity such as the
144	following:
145	delta-1 Cis or trans tetrahydrocannabinol, and their optical isomers;
146	delta-6 Cis or trans tetrahydrocannabinol, and their optical isomers;
147	delta-3,4 Cis or trans tetrahydrocannabinol, and its optical isomers;
148	(Since nomenclature of these substances is not internationally standardized, compounds
149	of these structures, regardless of numerical designation of atomic positions covered.)
150	Ethylamine analog of phencyclidine; some trade or other names: N-ethyl-1-

152	cyclohexamine, PCE;
153	Pyrrolidine analog of phencyclidine; some trade or other names: 1-(1-phenylcyclohexyl)-
154	pyrrolidine, PCPy, PHP;
155	Thiophene analog of phencyclidine; some trade or other names: 1-[1-(2-thienyl)-
156	cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine; TPCP, TCP;
157	1[1-(2-thienyl)cyclohexyl]pyrroldine; some other names: TCPy.
158	4-methylmethcathinone (Mephedrone);
159	3,4-methylenedioxypyrovalerone (MDPV);
160	2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);
161	2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)
162	2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)
163	2-(4-lodo-2,5-dimethoxyphenyl)ethanamine (2C-l)
164	2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2)
165	2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4)
166	2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)
167	2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N)
168	2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P)
169	3,4-Methylenedioxy-N-methylcathinone (Methylone)
170	2,5-dimethoxy-4-(n)-propyltghiophenethylamine (2C-T-7, itsoptical isomers, salts and
171	salts of isomers
172	5-methoxy-N,N-dimethyltryptamine some trade or other names: 5-methoxy-3-[2-
173	(dimethylamino)ethyl]indole; 5-MeO-DMT(5-MeO-DMT)
174	Alpha-methyltryptamine (other name: AMT)
175	5-methoxy-N,N-diisopropyltryptamine (other name: 5-MeO-DIPT)
176	Synthetic Cannabinoids as follows:

```
177
              2-[(1R,3S)-3-hydroxycyclohexyl]-5- (2-methyloctan-2-yl)phenol) {also known as CP
178
       47,497 and homologues);
179
              rel-2-[(1S,3R)-3-hydroxycyclohexyl] -5-(2-methylnonan-2-yl)phenol {also known as CP
180
       47,497-C8 homolog);
181
              [(6aR)-9-(hydroxymethyl)-6,
                                               6-dimethyl-3-(2-methyloctan-2-yl)-6a,
                                                                                         7,10,10a-
182
       tetrahydrobenzo[c]chromen-1-ol)] {also known as HU-210};
183
              (dexanabinol);
184
              (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
185
       tetrahydrobenzol[c]chromen-1-ol) {also known as HU-211};
186
              1-Pentyl-3-(1-naphthoyl)indole {also known as JWH-018}:
187
              1-Butyl-3-(1-naphthoyl)indole {also known as JWH-073};
188
              (2-methyl-1-propyl-1H-indol-3-yl)-1-napthalenyl-methanone {also known as JWH-015};
              (1-hexyl-1H-indol-3-yl)-1-naphthalenyl-methanone {also known as JWH-019};
189
190
              [1-[2-(4-morpholinyl) ethyl] -1H-indol-3-yl]-1-naphthalenyl-methanone {also known as
191
       JWH-200};
192
              1-(1-pentyl-1H-indol-3-yl)-2-(3-hydroxyphenyl)-ethanone {also known as JWH-250};
              2-((1S,2S,5S)-5-hydroxy-2- (3-hydroxtpropyl)cyclohexyl) -5-(2-methyloctan-2-yl)phenol
193
194
       {also known as CP 55,940};
195
              (4-methyl-1-naphthalenyl) (1-pentyl-1H-indol-3-yl) -methanone {also known as JWH-122};
196
              (4-methyl-1-naphthalenyl) (1-pentyl-1H-indol-3-yl) -methanone {also known as JWH-398;
197
              (4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone {also known as RCS-4};
198
              1-(1-(2-cyclohexylethyl) -1H-indol-3-yl) -2-(2-methoxyphenyl) ethanone {also known as
199
       RCS-8};
200
              1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081);
201
              1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201); and
202
              1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM694).
```

203	Synthetic cannabinoids:
204	CP 47,497 AND homologues, 2-[(1R,3S)-3-Hydroxycyclohexyl]-5-(2-methyloctan-2-
205	YL)phenol);
206	HU-210, [(6AR,10AR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-Methyloctan-2-YL)-6A,7,10,
207	10A-tetrahydrobenzo[C] chromen-1-OL)];
208	HU-211, (dexanabinol, (6AS,10AS)-9-(hydroxymethyl)-6,6-Dimethyl-3-(2-methyloctan-2-
209	YL)-6A,7,10,10atetrahydrobenzo[C]chromen-1-OL);
210	JWH-018, 1-pentyl-3-(1-naphthoyl)indole;
211	JWH-019, 1-hexyl-3-(1-naphthoyl)indole;
212	JWH-073, 1-butyl-3-(1-naphthoyl)indole;
213	JWH-200, (1-(2-morpholin-4-ylethyl)indol-3-yl)- Naphthalen-1-ylmethanone;
214	JWH-250, 1-pentyl-3-(2-methoxyphenylacetyl)indole.]
215	Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (5F-
216	ADB);
217	Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (5F-AMB);
218	Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (FUB-
219	AMB);
220	N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5F-APINACA);
221	N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide
222	(ADB-FUBINACA);
223	Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate
224	(MDMB-CHMICA);
225	Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate
226	(MDMB-FUBINACA);
227	Tetrahydrocannabinols:
228	DELTA-1 CIS OR trans tetrahydrocannabinol and their Optical isomers.

229	DELTA-6 CIS OR trans tetrahydrocannabinol and their optical isomers.
230	DELTA-3,4 CIS or their trans tetrahydrocannabinol and their optical isomers.
231	Synthetic Phenethylamines
232	2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe/ 2C-I-
233	NBOMe);
234	2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe/2C-C-
235	NBOMe);
236	2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe/ 2C-B-
237	NBOMe);
238	Synthetic Opioids (icluding their isomers, esters, ethers, salts and salts of isomers, esters
239	and ethers):
240	N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl);
241	furanyl fentanyl;
242	3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (also known as U-
243	47700);
244	N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide, also known as N-(1-
245	phenethylpiperidin-4-yl)-N-phenylbutanamide, (butyryl fentanyl);
246	N-[1-[2-hydroxy-2-(thiophen-2-yl)ethylpiperidin-4-yl]-N-phenylpropionamide, also known
247	as N-[1-[2-hydroxy-2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenylpropanamide, (beta-
248	hydroxythiofentanyl).
249	N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acryl fentanyl)
250	N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide (isobutyryl fentanyl)
251	N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide (cyclopropyl fentanyl)
252	2-(2,4-dichlorophenyl)-N-((1S,2S)-2-(dimethylamino)cyclohexyl)-N-methylacetamide
253	(also known as U-48800)

254 Trans-3,4-dichloro-N-[2-(diethylamino)cyclohexyl]-N-methyl-benzamide (also known as U-49900) 255 256 Trans-3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methyl-benzeneacetamide (also 257 known as U-51754) 258 Opioid Receptor Agonist 259 AH-7921 (3,4-dichloro-N- (1dimethylamino)cyclohexylmethyl]benzamide). 260 Naphthoylindoles or any compound containing a 3-(-1- Napthoyl) indole structure with 261 substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent. This shall 262 263 include the following: 264 JWH 015; 265 JWH 018; 266 JWH 019; 267 JWH 073; 268 JWH 081; 269 JWH 122; 270 JWH 200; 271 JWH 210; 272 JWH 398; 273 AM 2201; 274 WIN 55,212. 275 Naphylmethylindoles or any compound containing a 1hindol-3-yl-(1-naphthyl) methane 276 structure with a substitution at the nitrogen atom of the indole ring whether or not further 277 substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to 278 any extent. This shall include, but not be limited to, JWH 175 and JWH 184.

Naphthoylpyrroles or any compound containing a 3-(1- Naphthoyl) pyrrole structure with substitution at the nitrogen atom of the pyrrole ring whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent. This shall include, but not be limited to, JWH 147 and JWH 307.

Naphthylmethylindenes or any compound containing a Naphthylideneindene structure with substitution at the 3- Position of the indene ring whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent. This shall include, but not be limited to, JWH 176.

Phenylacetylindoles or any compound containing a 3- Phenylacetylindole structure with substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. This shall include the following:

RCS-8, SR-18 OR BTM-8;

292 JWH 250;

279

280

281

282

283

284

285

286

287

288

289

290

291

296

297

298

299

300

302

303

293 JWH 203;

294 JWH 251;

295 JWH 302.

Cyclohexylphenols or any compound containing a 2-(3- hydroxycyclohexyl) phenol structure with a substitution at the 5-position of the phenolic ring whether or not substituted in the cyclohexyl ring to any extent. This shall include the following:

CP 47,497 and its homologues and analogs;

Cannabicyclohexanol;

301 CP 55,940.

Benzoylindoles or any compound containing a 3-(benzoyl) indole structure with substitution at the nitrogren atom of the indole ring whether or not further substituted in the indole

304 ring to any extent and whether or not substituted in the phenyl ring to any extent. This shall include 305 the following: 306 AM 694; 307 Pravadoline WIN 48,098; 308 RCS 4; 309 AM 679. 310 [2,3-dihydro-5 methyl-3-(4-morpholinylmethyl)pyrrolo [1,2,3-DE]-1, 4-benzoxazin-6-YL]-1-311 napthalenymethanone. This shall include WIN 55,212-2. 312 Dibenzopyrans or any compound containing a 11-hydroxydelta 8-tetrahydrocannabinol 313 structure with substitution on the 3-pentyl group. This shall include HU-210, HU-211, JWH 051 314 and JWH 133. 315 Adamantoylindoles or any compound containing a 3-(-1- Adamantoyl) indole structure with 316 substitution at the nitrogen atom of the indole ring whether or not further substituted in the 317 adamantoyl ring system to any extent. This shall include AM1248. 318 Tetramethylcyclopropylindoles compound Α 3or any containing 319 tetramethylcyclopropylindole structure with substitution at the nitrogen atom of the indole ring 320 whether or not further substituted in the indole ring to any extent and whether or not substituted 321 in the tetramethylcyclopropyl ring to any extent. This shall include UR-144 and XLR-11. 322 N-(1-Adamantyl)-1-pentyl-1h-indazole-3-carboxamide. This shall include AKB48. 323

Any other synthetic chemical compound that is a Cannabinoid receptor type 1 agonist as demonstrated by binding studies and functional assays that is not listed in Schedules II, III, IV and V, not federal Food and Drug Administration approved drug or used within legitimate, approved medical research. Since nomenclature of these substances is not internationally standardized, any immediate precursor or immediate derivative of these substances shall be covered.

Tryptamines:

324

325

326

327

328

329

5- methoxy- N- methyl-N-isopropyltryptamine (5-MeO-MiPT)

330	4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT)
331	4-hydroxy-N-methyl-N-isopropyltryptamine (4-HO-MiPT)
332	4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET)
333	4-acetoxy-N,N-diisopropyltryptamine (4-AcO-DiPT)
334	5-methoxy-α-methyltryptamine (5-MeO-AMT)
335	4-methoxy-N,N-Dimethyltryptamine (4-MeO-DMT)
336	4-hydroxy Diethyltryptamine (4-HO-DET)
337	5- methoxy- N,N- diallyltryptamine (5-MeO-DALT)
338	4-acetoxy-N,N-Dimethyltryptamine (4-AcO DMT)
339	4-hydroxy Diethyltryptamine (4-HO-DET)
340	(e) Depressants.
341	Mecloqualone;
342	Methaqualone.
343	(f) Stimulants.
344	Aminorex; some other names: aminoxaphen; 2-amino-5- phenyl-2-oxazoline; or 4,5-
345	dihydro-5-phenyl-2-oxazolamine;
346	Cathinone; some trade or other names: 2-amino-1-phenyl-1- propanone, alpha-
347	aminopropiophenone, 2-aminopropiophenone and norephedrone;
348	Fenethylline;
349	Methcathinone, its immediate precursors and immediate derivatives, its salts, optical
350	isomers and salts of optical isomers; some other names: (2-(methylamino)-propiophenone; alpha-
351	(methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1- one; alpha
352	methylaminopropiophenone; monomethylpropion; 3,4-methylenedioxypyrovalerone and/or
353	mephedrone;3,4-methylenedioxypyrovalerone (MPVD); ephedrone; N-methylcathinone;
354	methylcathinone; AL-464; AL-422; AL- 463 and UR1432;
355	(+-) cis-4-methylaminorex; ((+-)cis-4,5-dihydro-4-methyl- 5-phenyl-2-oxazolamine);

356	N-ethylamphetamine;
357	N,N-dimethylamphetemine; also known as N,N-alpha- trimethyl-benzeneethanamine;
358	N,N-alpha-trimethylphenethylamine.
359	Alpha-pyrrolidinopentiophenone, also known as alpha-PVP, optical isomers, salts and
360	salts of isomers.
361	Substituted amphetamines:
362	2-Fluoroamphetamine
363	3-Fluoroamphetamine
364	4-Fluoroamphetamine
365	2-chloroamphetamine
366	3-chloroamphetamine
367	4-chloroamphetamine
368	2-Fluoromethamphetamine
369	3-Fluoromethamphetamine
370	4-Fluoromethamphetamine
371	4-chloromethamphetamine
372	(g) Temporary listing of substances subject to emergency scheduling. Any material,
373	compound, mixture or preparation which contains any quantity of the following substances:
374	N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl), its optical isomers, salts,
375	and salts of isomers.
376	N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl), its optical
377	isomers, salts and salts of isomers.
378	N-benzylpiperazine, also known as BZP.
379	Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide);
380	4-fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]-
381	butyramide);

382	Isobutyryl fentanyl (2-methyl-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]-propanamide);
383	Methoxyacetyl fentanyl (2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]-
384	acetamide);
385	3-methylbutyryl fentanyl (N-[3-methyl-1-(2-phenylethyl)piperidin-4-yl]-N-
386	phenylbutyramide);
387	4-methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-
388	yl)butyramide);
389	Ocfentanil (N-(2-fluorophenyl)-2-methoxy-N-[1-(2-phenylethyl)piperidin-4-yl]-acetamide);
390	Tetrahydrofuran fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-
391	carboxamide);
392	Valeryl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]pentanamide).
393	(h) The following controlled substances are included in Schedule I:
394	Synthetic Cathinones or any compound, except bupropion or compounds listed under a
395	different schedule, or compounds used within legitimate and approved medical research,
396	structurally derived from 2- Aminopropan-1-one by substitution at the 1-position with Monocyclic
397	or fused polycyclic ring systems, whether or not the compound is further modified in any of the
398	following ways:
399	By substitution in the ring system to any extent with Alkyl, alkylenedioxy, alkoxy, haloalkyl,
400	hydroxyl or halide Substituents whether or not further substituted in the ring system by one or
401	more other univalent substituents.
402	By substitution at the 3-position with an acyclic alkyl substituent.
403	By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl or methoxybenzyl
404	groups.
405	By inclusion of the 2-amino nitrogen atom in a cyclic structure.
406	Any other synthetic chemical compound that is a Cannabinoid receptor type 1 agonist as
407	demonstrated by binding studies and functional assays that is not listed in Schedules II, III, IV and

V, not federal Food and Drug Administration approved drug or used within legitimate, approved medical research. 409

CHAPTER 61. CRIMES AND THEIR PUNISHMENT.

ARTICLE 11. GENERAL PROVISIONS CONCERNING CRIMES.

§61-11-27. Expungement of certain cannabis offender records.

408

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

et seg. of this code.

(a) Upon the effective date of this section as adopted during the 2020 Regular Session of
the Legislature, the clerk of the circuit court and the prosecuting attorney of each county shall
review all arrest and conviction record of every cannabis offender of every person convicted of a
cannabis offense in this state beginning in calendar year 1937 to the present, and shall prepare
and execute the expungement of all cannabis offense records.
(b) Expungement of cannabis offender records shall be automatic, and a written
explanation of the expungement action shall be transmitted to the incarcerated cannabis offender,
and to the correctional facility where the offender is held, with an order compelling the release of
the cannabis offender, indicating the date of the release and providing the transitioning offender
a description of the transitional services available to him or her as required pursuant to §51-12-1

(c) A released cannabis offender or a family member of a deceased cannabis offender, may petition to have all records of a cannabis conviction expunged beginning with any offense committed in or since calendar year 1937.

(d) Cannabis offenders may not be charged a fee for the expungement of any record of cannabis conviction. Upon request any cannabis offender shall have all records of cannabis offenses expunged: Provided, That crimes that involved issues of public safety or resulted in the harm of another, are exempt from the mandatory expungement provisions of this section.

NOTE: The purpose of this bill is to normalize cannabis regulation, permitting the personal use of cannabis, providing for transitional services for former cannabis offenders and

providing for the expungement of cannabis offender criminal records.

Strike-throughs indicate language that would be stricken from a heading or the present law and underscoring indicates new language that would be added.